Dec 10, 2024, 14:09
Jordi Remon: Alectinib vs crizotinib in 1st line in Asian patients with ALK+ NSCLC
Jordi Remon, Thoracic oncologist at CIOCC Barcelona, shared on X:
“ALESIA Trial: Alectinib vs crizotinib in 1st line in Asian patients with ALK+ NSCLC. OS: NE alectinib vs 81 mo. crozotinib!! Yes with crizotinib. Difference not significant. What would be the CROWN trial (Lorlatinib vs Crizo) if comparator was alectinib?”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 11, 2024, 10:44
Dec 11, 2024, 10:22
Dec 11, 2024, 10:04
Dec 11, 2024, 09:53